NCT06658626View on ClinicalTrials.gov

A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)

PHASE1CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions

Healthy

Interventions

DRUG

[¹⁴C]Enlicitide chloride

IV Injection

Trial Locations (1)

53704

Labcorp Clinical Research Unit Inc. (Site 0001), Madison

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY